Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2006 by Heidelberg University.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Merck KGaA
Information provided by:
Heidelberg University
ClinicalTrials.gov Identifier:
NCT00311857
First received: April 5, 2006
Last updated: September 7, 2006
Last verified: September 2006
  Purpose

GERT is a one-armed single-center phase I/II trial. In a first step, dose-escalation of TMZ from 50 mg/m2 to 75mg/m2 together with radiotherapy and cetuximab will be performed. Should safety be proven, the phase II trial will be initiated with the standard dose of 75mg/m2 of TMZ. Cetuximab will be applied in the standard application dose of 400mg/m2 in week 1, thereafter at a dose of 250mg/m2 weekly. A total of 46 patients will be included into this phase I/II trial.

Primary endpoints are feasibility and toxicity, secondary endpoints are overall and progression-free survival. An interim analysis will be performed after inclusion of 15 patients into the main study. Patients’ enrolment will be performed over a period of 2 years. The observation time will end 2 years after inclusion of the last patient.


Condition Intervention Phase
Glioblastoma Multiforme
Drug: Cetuximab
Drug: Temozolomide
Procedure: Radiation therapy
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Treatment of Primary Glioblastoma Multiforme With Cetuximab, Radiotherapy and Temozolomide (GERT) – Phase I/II Trial

Resource links provided by NLM:


Further study details as provided by Heidelberg University:

Primary Outcome Measures:
  • Toxicity

Secondary Outcome Measures:
  • Overall survival

Estimated Enrollment: 46
Study Start Date: February 2006
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • >= 18 and < 70 years of age
  • Karnofsky Performance Score >= 60
  • histologically confirmed supratentorial GBM
  • interval between primary diagnosis and registration for the study < 4 weeks
  • patients will be included according to the incidental gender distribution for patients with GBM of ♀/♂ 2:3
  • adequate blood values (not older than 14 days prior to initiation of RCHT)
  • neutrophil count (ANC) ≥1500/mm3 or white blood cells (WBC) ≥2000/mm3
  • platelets ≥100.000/mm3
  • hemoglobin ≥10g/dL
  • BUN <1.5 times the upper range
  • Total and direct bilirubin <1.5times the upper laboratory limit
  • Adequate liver enzymes <3 times the upper laboratory limit
  • Life expectancy >12 weeks
  • Written informed consent

Exclusion Criteria:

  • refusal of the patients to take part in the study
  • previous radiotherapy of the brain or chemotherapy with DTIC or TMZ
  • known allergy against extrinsical proteins
  • previous chemotherapy or therapy with an EGFR-inhibitor
  • Previous antibody therapy
  • Patients who have not yet recovered from acute toxicities of prior therapies
  • Acute infections requiring systemic application of antibiotics
  • Frequent vomiting or a medical condition preventing the oral application of TMZ
  • Clinically active kidney- liver or cardiac disease
  • Known carcinoma < 5 years ago (excluding Carcinoma in situ of the cervix, basal cell carcinoma, squamous cell carcinoma of the skin)
  • HIV
  • Pregnant or lactating women
  • Participation in another clinical study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00311857

Contacts
Contact: Daniela Schulz-Ertner, MD +49-6221-56 ext 8201 Daniela.Ertner@med.uni-heidelberg.de
Contact: Stephanie E Combs, MD +49-6221-56 ext 8201 Stephanie.Combs@med.uni-heidelberg.de

Locations
Germany
University of Heidelberg Recruiting
Heidelberg, Baden-Württemberg, Germany, 69120
Contact: Daniela Schulz-Ertner, MD    +49-6221-56 ext 8201    Daniela.Ertner@med.uni-heidelberg.de   
Contact: Stephanie E Combs, MD    +49-6221-56 ext 8201    Stephanie.Combs@med.uni-heidelberg.de   
Principal Investigator: Daniela Schulz-Ertner, MD         
Sub-Investigator: Stephanie E Combs, MD         
Sponsors and Collaborators
Heidelberg University
Merck KGaA
Investigators
Principal Investigator: Daniela Schulz-Ertner, MD Heidelberg University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00311857     History of Changes
Other Study ID Numbers: Eudract-2005-003911-63, PEI 119/01
Study First Received: April 5, 2006
Last Updated: September 7, 2006
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Heidelberg University:
Cetuximab

Additional relevant MeSH terms:
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Cetuximab
Temozolomide
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 30, 2014